What is ANI Pharmaceuticals's pre-tax income?

ANI Pharmaceuticals (ANIP) reported pre-tax income of $40.22M in Q1 2026.

How has ANI Pharmaceuticals's pre-tax income changed year-over-year?

ANI Pharmaceuticals's pre-tax income increased by 101.2% year-over-year, from $19.99M to $40.22M.

What is the long-term trend for ANI Pharmaceuticals's pre-tax income?

Over 4 years (2021 to 2025), ANI Pharmaceuticals's pre-tax income has grown at a 14.3% compound annual growth rate (CAGR), from -$56.06M to $95.79M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

ANI Pharmaceuticals ANIP Pre-Tax Income

Pre-Tax Income at other companies

Amneal Pharmaceuticals, Inc.AMRX

$80.18M+114%

ViatrisVTRS

-$247.3M+92.0%

AnaptysBio, Inc.ANAB

-$52.84M-34.5%

ALN

Alnylam PharmaceuticalsALNY

$221.65M+9,460%

Aurinia PharmaceuticalsAUPH

$43.93M+80.4%

AmgenAMGN

$2.08B+5.6%

Segments

By segment

See full

Generics and Other$40.32M-16.9%

Rare Disease and Brands$36.25M+71.5%

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.89B+18.3%

Enterprise value$1.88B+5.8%

P/E20.5×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's pre-tax income?: ANI Pharmaceuticals (ANIP) reported pre-tax income of $40.22M in Q1 2026.
How has ANI Pharmaceuticals's pre-tax income changed year-over-year?: ANI Pharmaceuticals's pre-tax income increased by 101.2% year-over-year, from $19.99M to $40.22M.
What is the long-term trend for ANI Pharmaceuticals's pre-tax income?: Over 4 years (2021 to 2025), ANI Pharmaceuticals's pre-tax income has grown at a 14.3% compound annual growth rate (CAGR), from -$56.06M to $95.79M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.